Biopharma Quarterly Deal-making Statistics, Q4 2017
A look at financing, M&A and alliance activity October–December 2017
Executive Summary
Biopharma financing finished off 2017 strong with a total value of $14.5 billion in Q4, led again by FOPOs. CVS' massive $77 billion acquisition of Aetna resulted in an all-time quarterly high in the M&A category, and the largest alliances were dominated by the development of vaccines and antibodies.
You may also be interested in...
Expanded Access Data Supported Lutathera Approval, US FDA Notes
Amid broader debate on right-to-try legislation, review experience of Novartis' oncologic highlights US FDA's argument that expanded access can at least in part contribute to approval of a drug.
Biopharma 2018: Is There Still A Place For Pharma In The New Health Care Economy?
2018 will be a time of transition in health care, when biopharma’s counterparts in adjacent industry segments scale up in a radical redesign of their traditional business models. Biopharma is not moving as quickly, and it confronts a strategic dilemma on how to address the prospect of a much more powerful set of rivals in the ongoing battle to own the patient experience in medicine.
Novo Outbid As Sanofi Agrees €3.9bn Ablynx Acquisition
Sanofi is to acquire Belgian nanobody developer Ablynx in an all-cash deal worth €3.9bn, 50% higher than the spurned bid by Novo Nordisk.